How Long Does Semaglutide Take to Work? The Benefit Timeline

"How long until it works" is the most-asked question about these drugs and the one most often answered with anecdote. The trials tracked it precisely. Here is what their curves show, benefit by benefit.

The honest headline#

Weeks for appetite. Months for weight. Over a year to the plateau. Years for cardiovascular benefit to accrue.

Nothing in this evidence base supports a meaningful result in days.

First weeks: dose escalation, not full effect#

Both trial programmes started participants low and stepped up over several weeks before reaching the maintenance amount, specifically to improve gastrointestinal tolerability. STEP 1 used a 16-week escalation before its maintenance phase^[1].

This matters for expectations in two ways. Early weeks reflect a lower exposure than the headline figure, so early results understate the eventual effect. And the appetite changes people report during this period are real but precede most of the measurable weight change.

Months: the weight curve#

This is the part worth internalising, because it is where expectations most often break.

In STEP 1, mean weight declined steadily and continuously across the trial, flattening in the final months toward the −14.9% endpoint at 68 weeks^[1].

In SURMOUNT-1, the decline ran to −15.0% through −20.9% by dose at 72 weeks, and at the higher doses weight was still drifting down near the endpoint rather than fully flat^[2].

The head-to-head SURMOUNT-5 trial ran to the same 72-week horizon: −20.2% versus −13.7%^[3].

The practical reading: these are year-plus trajectories. Someone at week 12 comparing themselves to a headline number from week 68 is comparing against a different point on the curve.

Faster than weight: glycaemic control#

In type 2 diabetes, HbA1c improvement appears well before most of the weight change — within weeks of reaching maintenance dosing, since the drugs act directly on glucose-dependent insulin secretion and glucagon rather than working through weight. If the goal is glycaemic, the timeline is shorter than the weight timeline.

Years: cardiovascular benefit#

SELECT followed 17,604 adults for a mean of 39.8 months. The 20% reduction in major adverse cardiovascular events accrued across that period as event curves separated over months^[4].

Nobody experiences a cardiovascular benefit as a felt event on a given week. It is a shifted probability accumulating over years, which is a different kind of benefit from a number on a scale — and worth understanding as such before judging whether treatment is "working".

The timeline that runs backwards#

Discontinuation has been measured too, and it moves faster than the gain did.

STEP 1's off-treatment extension followed participants for a year after stopping: roughly two-thirds of the lost weight returned^[5].

SURMOUNT-4 tested it as a randomised withdrawal — about 14% of body weight regained over 52 weeks on placebo, while those continuing kept losing^[6].

The timeline at a glance#

Three things that change your personal timeline#

• Individual variation is wide. Every figure above is a mean. Trial participants ranged from substantial responders to non-responders around each of these averages.
• Dose matters and takes time to reach. The highest-dose arms produced the largest effects, and escalation to them was deliberately gradual.
• Trials come with structured support. Participants received lifestyle counselling as part of the protocol. The curves reflect drug plus that scaffolding.

Where to go next#

• Peptides for weight loss — the numbers and what happens when you stop.
• GLP-1 benefits beyond weight loss — heart, kidney, liver, sleep.
• Semaglutide vs tirzepatide
• Semaglutide profile · Tirzepatide profile